Decentralizing Inner-Product Functional Encryption

International audienceMulti-client functional encryption (MCFE) is a more flexible variant of functional encryption whose functional decryption involves multiple ciphertexts from different parties. Each party holds a different secret key and can independently and adaptively be corrupted by the adversary. We present two compilers for MCFE schemes for the inner-product functionality, both of which support encryption labels. Our first compiler transforms any scheme with a special key-derivation property into a decentralized scheme, as defined by Chotard et al. (ASIACRYPT 2018), thus allowing for a simple distributed way of generating functional decryption keys without a trusted party. Our second compiler allows to lift an unnatural restriction present in existing (decentralized) MCFE schemes, which requires the adversary to ask for a ciphertext from each party. We apply our compilers to the works of Abdalla et al. (CRYPTO 2018) and Chotard et al. (ASIACRYPT 2018) to obtain schemes with hitherto unachieved properties. From Abdalla et al., we obtain instantiations of DMCFE schemes in the standard model (from DDH, Paillier, or LWE) but without labels. From Chotard et al., we obtain a DMCFE scheme with labels still in the random oracle model, but without pairings

Development of a Mouse Monoclonal Antibody Cocktail for Post-exposure Rabies Prophylaxis in Humans

As the demand for rabies post-exposure prophylaxis (PEP) treatments has increased exponentially in recent years, the limited supply of human and equine rabies immunoglobulin (HRIG and ERIG) has failed to provide the required passive immune component in PEP in countries where canine rabies is endemic. Replacement of HRIG and ERIG with a potentially cheaper and efficacious alternative biological for treatment of rabies in humans, therefore, remains a high priority. In this study, we set out to assess a mouse monoclonal antibody (MoMAb) cocktail with the ultimate goal to develop a product at the lowest possible cost that can be used in developing countries as a replacement for RIG in PEP. Five MoMAbs, E559.9.14, 1112-1, 62-71-3, M727-5-1, and M777-16-3, were selected from available panels based on stringent criteria, such as biological activity, neutralizing potency, binding specificity, spectrum of neutralization of lyssaviruses, and history of each hybridoma. Four of these MoMAbs recognize epitopes in antigenic site II and one recognizes an epitope in antigenic site III on the rabies virus (RABV) glycoprotein, as determined by nucleotide sequence analysis of the glycoprotein gene of unique MoMAb neutralization-escape mutants. The MoMAbs were produced under Good Laboratory Practice (GLP) conditions. Unique combinations (cocktails) were prepared, using different concentrations of the MoMAbs that were capable of targeting non-overlapping epitopes of antigenic sites II and III. Blind in vitro efficacy studies showed the MoMab cocktails neutralized a broad spectrum of lyssaviruses except for lyssaviruses belonging to phylogroups II and III. In vivo, MoMAb cocktails resulted in protection as a component of PEP that was comparable to HRIG. In conclusion, all three novel combinations of MoMAbs were shown to have equal efficacy to HRIG and therefore could be considered a potentially less expensive alternative biological agent for use in PEP and prevention of rabies in humans